Get the Stockscreener App
4.26
1.19%
0.05
After Hours:
4.28
0.02
+0.47%
Trevi Therapeutics Inc stock is traded at $4.26, with a volume of 264.05K.
It is up +1.19% in the last 24 hours and down -1.39% over the past month.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
See More
Previous Close:
$4.21
Open:
$4.23
24h Volume:
264.05K
Relative Volume:
0.16
Market Cap:
$380.70M
Revenue:
-
Net Income/Loss:
$-29.07M
P/E Ratio:
-14.69
EPS:
-0.29
Net Cash Flow:
$-31.85M
1W Performance:
+9.23%
1M Performance:
-1.39%
6M Performance:
+63.22%
1Y Performance:
+191.78%
1-Day Range:
$4.13
$4.28
1-Week Range:
$3.81
$4.295
52-Week Range:
$1.39
$4.68
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Name
Trevi Therapeutics Inc
Sector
Industry
Phone
203-304-2499
Address
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
4.26 | 380.70M | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-30-24 | Initiated | Raymond James | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-12-23 | Initiated | B. Riley Securities | Buy |
| Nov-22-22 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | BMO Capital Markets | Outperform |
| Jun-03-19 | Initiated | Needham | Buy |
| Jun-03-19 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | Stifel | Buy |
View All
Trevi Therapeutics Inc Stock (TRVI) Latest News
President & CEO GOOD JENNIFER L sale 4,219 shares of Trevi Therapeutics Inc [TRVI] - Knox Daily
A closer look at Trevi Therapeutics Inc (TRVI)’s stock price trends - US Post News
Trevi Therapeutics Inc (TRVI) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
JPMorgan Chase & Co. Buys 69,167 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Short Interest Down 17.0% in January - MarketBeat
JPMorgan Chase & Co. Has $336,000 Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Certain Common Stock Warrants: of Trevi Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 31-JAN-2025. - Marketscreener.com
Certain Pre-funded Warrants of Trevi Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 31-JAN-2025. - Marketscreener.com
Certain Stock Options of Trevi Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 31-JAN-2025. - Marketscreener.com
Chronic Refractory Cough Pipeline 2024: In-depth Clinical - openPR
Trevi Therapeutics to Participate in Upcoming February Investor Conferences - StockTitan
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $9.31 Consensus Target Price from Brokerages - Defense World
Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
Analysts Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Target Price at $9.31 - MarketBeat
FY2024 Earnings Forecast for TRVI Issued By Leerink Partnrs - Defense World
What is Leerink Partnrs' Forecast for TRVI FY2024 Earnings? - MarketBeat
Trevi Therapeutics Announces Abstract Presentation at the Americ - GuruFocus.com
Barclays PLC Acquires 61,317 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Short Interest in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Decreases By 17.0% - MarketBeat
Jane Street Group LLC Sells 33,439 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics’ (TRVI) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Trevi Therapeutics’ $50 Million Common Stock Offering - Global Legal Chronicle
Trevi Therapeutics stock target lifted, holds Buy on treatment progress By Investing.com - Investing.com Canada
What Makes Trevi Therapeutics (TRVI) a New Buy Stock - Yahoo Finance
Trevi Therapeutics (NASDAQ:TRVI) Receives "Buy" Rating from D. Boral Capital - MarketBeat
Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference - Nasdaq
Trevi Therapeutics (TRVI) Stock Price, News & Analysis - MarketBeat
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - GuruFocus.com
Geode Capital Management LLC Increases Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - MarketBeat
Geode Capital Management LLC Has $4.22 Million Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Barclays PLC Raises Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics stock soars to 52-week high of $4.68 By Investing.com - Investing.com Australia
Trevi Therapeutics stock soars to 52-week high of $4.68 - Investing.com India
Trevi Therapeutics Announces Oral Presentation on Data from Ph2a - GuruFocus.com
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
State Street Corp Has $3.18 Million Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Retail Chatter For Trevi Therapeutics Soars After Enrollment Target For Chronic Cough Study Hits 75% - MSN
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Sees Large Increase in Short Interest - MarketBeat
Trevi Therapeutics Reports Second Quarter 2024 Financial Results - GuruFocus.com
BNP Paribas Financial Markets Purchases 6,764 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Cough in Idiopathic Pulmonary Pipeline Report 2024: Clinical Trials Progress and Therapies by DelveInsight | Algernon Pharma, Seyltx, Melius Pharma, NeRRe Therapeutics, Trevi Therapeutics - Barchart
Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024 - The Eastern Progress Online
Trevi Therapeutics sets $50 million stock offering price By Investing.com - Investing.com Australia
Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024 - The Eastern Progress Online
Form 424B5 Trevi Therapeutics, Inc. - StreetInsider.com
Trevi Therapeutics Prices of $50 Million Underwritten Offering - citybiz
Trevi Therapeutics sets $50 million stock offering price - Investing.com
Trevi Therapeutics Inc Stock (TRVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):